This post is intended for VFC's Stock House only. No re-publishings or re-postings are authorized. Also see News, Notes & Weekly Stock Watch at VFC's NEW Stock House.
CPST: Capstone Turbine announced last week that quarterly earnings will be released on June 14th, to be followed by a conference call to discuss the results.
Capstone has banked some large orders during the course of 2011 so far, and has drawn a whole lot of new attention since being mentioned by President Obama earlier this year in a speech in Brazil.
The stock has already retreated back from the two dollar mark - a mark that CPST has failed to hold after surpassing it a couple of times - but any better-than-expected results from the quarterly report might be enough to boost CPST over the two dollar mark for good.
There's quite the backlog of orders to work through still, and investors will be looking to see if the company is moving through that backlog any quicker as the company shoots for profitability.
Disclosure: Long CPST.
CTSO: Hard to ignore the fact that Cytosorbents slipped back to the eighteen cents mark - where it traded before the CE Mark Approval in Europe was announced earlier this year.
Cautious statements by both the company and investors over the past few weeks have a fair share of skepticism surrounding the stock, but there are still a couple of facts that remain that cannot be ignored for the positive potential:
- The approval came as a surprise, and before the trial was complete. That's an indication, in my opinion, that the primary results looked pretty solid to garner approval for the device.
- Indications are that CTSO was being heavily naked-shorted. It only makes sense that those that missed the boat on the first run would do all in their power to beat the price back down to buyable levels again. A lot of effort was made to keep a lid on this one, and it's gotta make you wonder why.
Keep an eye out for an update from the company. No one expected CytoSorb to be on the market right away, so there's plenty of time for the stock to regroup and consolidate. Back under twenty, I like it as a BUY again.
That said, it's about crunch time that investors need an update, or a release of the secondary endpoints.
I've got patience with this one. Readers of this blog saw that I was becoming skeptical before the approval news, but I think this company is onto something; it might just take a little while to work through all the European red tape before hitting the market in force.
On that note, a deep-pocketed partner could assist this little company with all of that.
Disclosure: Long CTSO.
GNBT: With a reverse split looming, and no real news on the horizon aside from the Antigen Express spin-off, GNBT could be in for a significant dip on the back end of the RS.
Might be worth taking a look at an entry point at that time, but with more Oral-lyn 'trialing' needed, and with AE-37 still far from market, the biggest catalysts that GNBT shareholders could hope for are still a ways away.
Disclosure: No position.
DDSS: Labopharm realized a nearly thirty percent gain on Friday, with significant volume, to boot, but whether a rebound is in order is debatable.
I formerly held a long position here, but bailed out a while back as the company changed strategic course mid-stream (similar to my reasons for bailing on Generex recently).
Since it looks like Labapharm is treating the Canadian approval of OLEPTRO as a PR-stunt - with no plans to commercialize the product - there may be little going for the company over the short term.
The thirty percent spike shows that DDSS could turn into a nice trading play, but I'm hesitant to hold this one until we see which track the company is going to take.
Right now it looks like the company is taking the 7 train to Citi, where the Mets are hanging out in the basement.
Disclosure: No position.
